Latest news with #commercial
Yahoo
4 hours ago
- Business
- Yahoo
Johnson & Johnson MedTech introduces automated system for surgical efficiency
Johnson & Johnson MedTech has introduced the KINCISE 2 Surgical Automated System, intended for use in knee and hip revision procedures, enhancing surgical efficiency. This tool aims to minimise the physical strain on surgeons during the procedures. It is designed to offer control and alleviate the load associated with manual impaction in primary and revision hip surgeries, as well as revision knee replacement surgeries. The company noted that surgeons in the field of orthopaedics are increasingly confronted with complex challenges in the operating room such as longer procedures, the physical demands of surgery, and higher case volumes. KINCISE 2 aims to address the issues of monotonous, high-force tasks, including repeated mallet strikes, which have been associated with overuse injuries, with the majority of surgeons reporting musculoskeletal pain, especially in their hands, neck, and lower back. Building on the company's first-generation KINCISE System, the new system features design elements such as increased reverse energy to aid in broach removal and push-to-lock adaptors to facilitate secure connections. According to the company, the Acetabular Cup Extraction addition positions the system as the first and only automated surgical impactor approved for the removal of well-fixed acetabular components, thereby widening its utility in complex hip revisions. Currently available for commercial use in the US, the system is equipped with a compact design and several grip options. Johnson & Johnson MedTech Orthopaedics company group chair Aldo Denti said: 'The KINCISE 2 System exemplifies the needs-based innovation we're bringing to orthopaedics this year. 'As more patients undergo joint replacements earlier in life, the demand for revision surgeries is rising. The KINCISE System has demonstrated the ability to help surgeons manage those complex cases by reducing operating time and providing procedural control - ultimately supporting better outcomes for patients.' Last month, the company launched the Soundstar Crystal ultrasound catheter in the US, which is intended for use in intracardiac echocardiography imaging during cardiac ablation procedures. "Johnson & Johnson MedTech introduces automated system for surgical efficiency" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 hours ago
- Business
- Yahoo
Johnson & Johnson MedTech introduces automated system for surgical efficiency
Johnson & Johnson MedTech has introduced the KINCISE 2 Surgical Automated System, intended for use in knee and hip revision procedures, enhancing surgical efficiency. This tool aims to minimise the physical strain on surgeons during the procedures. It is designed to offer control and alleviate the load associated with manual impaction in primary and revision hip surgeries, as well as revision knee replacement surgeries. The company noted that surgeons in the field of orthopaedics are increasingly confronted with complex challenges in the operating room such as longer procedures, the physical demands of surgery, and higher case volumes. KINCISE 2 aims to address the issues of monotonous, high-force tasks, including repeated mallet strikes, which have been associated with overuse injuries, with the majority of surgeons reporting musculoskeletal pain, especially in their hands, neck, and lower back. Building on the company's first-generation KINCISE System, the new system features design elements such as increased reverse energy to aid in broach removal and push-to-lock adaptors to facilitate secure connections. According to the company, the Acetabular Cup Extraction addition positions the system as the first and only automated surgical impactor approved for the removal of well-fixed acetabular components, thereby widening its utility in complex hip revisions. Currently available for commercial use in the US, the system is equipped with a compact design and several grip options. Johnson & Johnson MedTech Orthopaedics company group chair Aldo Denti said: 'The KINCISE 2 System exemplifies the needs-based innovation we're bringing to orthopaedics this year. 'As more patients undergo joint replacements earlier in life, the demand for revision surgeries is rising. The KINCISE System has demonstrated the ability to help surgeons manage those complex cases by reducing operating time and providing procedural control - ultimately supporting better outcomes for patients.' Last month, the company launched the Soundstar Crystal ultrasound catheter in the US, which is intended for use in intracardiac echocardiography imaging during cardiac ablation procedures. "Johnson & Johnson MedTech introduces automated system for surgical efficiency" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
a day ago
- Business
- Associated Press
Linqura Announces Strategic Alliance with Voldico
Linqura to Empower Voldico's Independent Insurance Agencies to Win More Commercial Deals Through AI-Powered Solutions 'With Linqura's AI-powered technology... our agents have access to advanced AI tools that improve risk assessment, streamline policy placement, and strengthen client relationships.'— Jerry Vollmer, CEO of Voldico HARTFORD, CT, UNITED STATES, June 3, 2025 / / -- Linqura, the AI-powered growth engine designed to transform the business insurance landscape, today announced a strategic alliance with Voldico to provide its member agencies with the Linqura AI growth engine platform to empower agents and underwriters in precision risk decision-making. This collaboration strengthens Linqura's commitment to redefining the commercial insurance landscape through innovation and operational efficiency. 'This partnership affirms our mission to empower every agent with the confidence and capabilities of a specialist on every account, driving unmatched growth potential,' said Mark Stender, CEO and Founder of Linqura. 'Voldico understands that open AI tools fall short when it comes to the complexities of business insurance. Together, we're delivering independent agencies the specialized knowledge they need to compete and succeed in today's commercial markets.' Key Partnership Benefits Instant Access to Commercial Lines Expertise Voldico member agencies gain access to LinqCo-pilot's proprietary: ○ 1,100+ NAICS code classification system ○ Carrier-specific submission guidance ○ Real-time coverage recommendations Demonstrated Performance Outcomes Early pilot agencies have achieved: ○ 83% accuracy in business classification (vs. 52% industry average) ○ Reduction from 5+ to 1 follow-up per submission ○ 30% faster binding times Network-Exclusive Advantages Voldico members receive: ○ Priority onboarding ○ Specialized training programs ○ Custom integration support 'Linqura's AI-powered technology aligns perfectly with Voldico's mission to empower independent agents, said Jerry Vollmer, CEO of Voldico. 'Through this partnership, our agents have access to advanced AI tools that improve risk assessment, streamline policy placement, and strengthen client relationships.' LinqCo-pilot is now available to Voldico member agencies. About Linqura Linqura is the AI-powered growth engine transforming the business insurance landscape. By solving the industry's biggest challenges—premium leakage, process friction, and knowledge gaps—Linqura unlocks $80 billion in premium lift potential for insurers and agents. Our platform ensures proper coverage, streamlines workflows, and scales profitability, empowering insurers to grow smarter and faster. Linqura is reshaping how business insurance is bought, sold, and managed with AI-driven precision. To learn more about Linqura, visit About Voldico Founded in 2010, Voldico is an insurance agency network with over 130 independent agencies writing insurance in 35 states. Voldico provides its agents with access to industry-leading carriers, state-of-the-art technologies, and exceptional support, fostering growth and success in the competitive insurance market. Learn more: For media inquiries, please contact: Kim Morton First Division Marketing (518) 330-3262 [email protected] Mark Stender Linqura Inc. +1 860-365-6278 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Globe and Mail
4 days ago
- Business
- Globe and Mail
Is Palantir a Top AI Stock to Buy in June?
Palantir (NASDAQ: PLTR) has rapidly become one of the most popular artificial intelligence (AI) stocks in the market. It's up by more than 600% since the start of 2024 and has gained more than 60% so far in 2025 alone. Few stocks will ever match that sort of jaw-dropping performance, but now, many investors are wondering if it's too late to buy Palantir. I think there's one guiding metric that will inform investors whether it is or not, and the answer may surprise you. Palantir's AI growth is impressive Palantir provides its clients with an AI-powered data analytics software suite. While the ins and outs of what Palantir does are quite complicated, its platform can simply be described as data in, insights out. This basic concept isn't easy in practice, but it has earned Palantir a broad and growing customer base. Palantir's got its start assisting various governments around the world -- and such clients are still its most important customers. It has since then expanded into commercial markets and has seen success in that arena, particularly in the U.S. In Q1, Palantir's fastest growing segment was U.S. commercial, which saw revenue rise by 71% to $255 million. Its U.S. government accounts also saw significant growth, with revenue increasing by 45% to $373 million. One area where Palantir is lagging is global sales. This may not necessarily be Palantir's fault, as AI hasn't been as widely adopted as quickly by businesses worldwide (if you exclude China). Its total commercial sales were up 33% to $397 million in Q1, while total government sales increased by 45% to $487 million. Overall, it's still a rapidly growing business, and if its domestic revenues continue growing at the same pace they have been, Palantir will be just fine. Palantir's profitability has also improved recently, with its profit margin reaching a record high of 24% in Q1. PLTR Profit Margin (Quarterly) data by YCharts. To top it off, in conjunction with its Q1 report, Palantir's management team gave guidance for a strong Q2 -- it expects revenue to rise by 38% year over year. However, Palantir's management has a history of guiding low and then overdelivering, so investors shouldn't be too concerned that Q2's forecast growth rate is slower than Q1's 39%. All of these metrics point to Palantir as still being a successful investment, but there's one problem: the price tag. Palantir's stock is far too expensive As mentioned above, Palantir's stock is up by more than 600% since 2024 began, yet its revenue has only risen by 40% and net income is up 172%. In short, the market is willing to pay more for Palantir's stock than it did in 2024. This occurred by a mechanism known as multiple expansion. Palantir's stock now trades at jaw-dropping valuations. PLTR PS Ratio data by YCharts. Few stocks reach and sustain levels of 212 times forward earnings and nearly 100 times sales. Palantir's execution from here will have to be flawless and outperform expectations, or else the stock will get whacked. To illustrate how expensive Palantir's stock is, let's take a five-year outlook and assume that Palantir's profit margin improves to 30%, its growth rate stays at 40%, and its share count stays flat. Those are incredibly bullish projections, but we're giving Palantir the benefit of the doubt. Should those three things occur, in five years, Palantir will produce $16.8 billion in revenue and $5 billion in profits. That would be incredible growth, but if the stock simply stayed flat from now until then, it would be trading for 58 times earnings at that point, which is still quite expensive. There are so many better options out there for investors than Palantir. The company is growing like few others, but the price you'd have to pay for the stock today already has at least five years of incredible growth baked in. As a result, I think many other stocks will outperform Palantir over the next five years. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!* Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Yahoo
26-05-2025
- Business
- Yahoo
1 Mind-Blowing Metric Palantir Investors Must Know
Palantir is seeing massive growth from its government and U.S. commercial segments. The stock has a very high premium attached to it. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) has become one of the hottest stocks on Wall Street. Since the start of 2024, the stock has risen around 630%, making it one of the best performers in the entire market. If you've positioned yourself well enough to capture all of these returns, congratulations! But there is one mind-blowing metric that Palantir investors need to be aware of, and it may cause you to change what you're doing with Palantir shares. Palantir has risen to the top due to its dominance in deploying AI solutions for its clients. Although what Palantir actually does is quite complicated, it can easily be summed up as "data in, insights out." This simple explanation for Palantir's business requires a ton of artificial intelligence (AI) work in the middle, but the results are astounding. For one example, Wendy's used Palantir to solve a supply chain problem that used to "go on for weeks and days" and fixed it in five minutes. Heineken's chief operating officer stated that the company used Palantir AI to optimize delivery and shipping in just three months -- a task that previously took three years to accomplish. There are countless examples of Palantir transforming businesses, but it's also deeply involved in government. When it first started, governments were Palantir's primary clients, and it only recently pivoted to offering its technology to companies as well. Government revenue remains a key part of Palantir's business today, and it generates more revenue than its commercial segment. In Q1, government revenue grew 45% year over year to $487 million while commercial revenue rose 33% to $397 million. Those are impressive growth rates, especially with the government, as many of its clients in that division have been using Palantir's products for years. Additionally, government revenue is being realized globally. U.S. government revenue growth for the first quarter was 45% -- the same rate as the overall company. However, U.S. commercial growth far outpaced the global division's total, rising 71% year over year. This is a key trend, as U.S. commercial sales have been unstoppable. But that 71% growth metric in U.S. commercial sales isn't the mind-blowing metric I want investors to know; its valuation is. Although Palantir's stock price has risen around 630% since the start of 2024, revenue only increased by 40%. That's because the market is willing to pay more for Palantir's business than it did in the past. This is called multiple expansion, and causes the multiple on the stock to rise. That's exactly what has happened with Palantir's various valuation metrics. Whether you use Palantir's forward price-to-earnings (P/E) ratio or price-to-sales (P/S) ratio, Palantir's stock is unbelievably expensive, and investors should be concerned about an imminent crash. Few companies can sustain a high valuation level, and nearly all crash at some point due to extreme expectations. Let's do a quick check to see what assumptions are baked into the stock price: Let's assume Palantir can accelerate its revenue growth from 39% year over year in Q1 to 45%, and it can sustain that rate for the entire period. Palantir is still working toward optimizing profitability, but the best software companies achieve a 30% profit margin. So, we'll set that as Palantir's ending profit margin. We'll also ignore the effects of stock-based compensation. This is a bad assumption because Palantir's share count has risen by over 5% over the past year, but it gives Palantir the benefit of the doubt. If all three assumptions become true over five years, Palantir's revenue will grow from $3.1 billion to $20 billion, and profits will rise from $571 million to $6 billion. That is monster growth, but does it justify today's valuation? If Palantir could generate $20 billion in revenue and $6 billion in profits, it would be valued at 14 times sales and 48 times earnings. Those are far more typical valuations for a growth stock, and nearly match what Nvidia trades at today (25 times sales and 45 times earnings). Because this calculation ignores stock-based compensation effects, the actual valuation will be much higher, so it's safe to assume that at least five years of growth are baked into the stock price if even the most bullish predictions come true. The mind-blowing metric I want investors to be aware of is five years -- the amount of time it will take to work out all of the growth baked into Palantir's stock. This is far too high a premium to pay for a stock, and I think investors would be smart to move on from it here, or at least trim back some of the gains, as few stocks ever work out for investors that are valued this high. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Keithen Drury has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy. 1 Mind-Blowing Metric Palantir Investors Must Know was originally published by The Motley Fool Sign in to access your portfolio
